Hydrocodone Combination Product Rescheduling: The Bigger Picture

Published Online: Friday, January 31, 2014
Follow Pharmacy_Times:
In this video, Jeff Fudin, PharmD, FCCP, adjunct associate professor at the Albany College of Pharmacy and adjunct assistant professor at the UCONN School of Pharmacy, argues that categorizing hydrocodone combination products as Schedule II will not make the medications safer for patients. Instead, he argues, there should be more education for those who prescribe the medications and pharmacists who dispense them.
 
This is the last in a series of 12 videos in which Dr. Fudin argues against categorizing hydrocodone combination products as Schedule II drugs, and Mary Lynn McPherson, PharmD, argues in favor of doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
Because orally administered morphine is associated with a significantly greater number of adverse events, ibuprofen is the better choice for relieving pain in children with broken bones.
Roughly two-thirds of emergency department admissions for overdoses involve prescription opioid medications.
It is compulsory for pharmacists to counsel all patients receiving opioids, evaluate the potential benefit of a naloxone reversal device, and contact the opioid prescriber if such a device is deemed appropriate.
Used alongside antidepressants, OTC analgesics and anti-inflammatories purchased from pharmacies may effectively treat patients with depression without increasing their risk of adverse events.
Latest Issues
$auto_registration$